PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease ReportsNeoplasm metastasis
MeSH D009362 - neoplasm metastasis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D009385:Neoplastic processes
$
Success rate
D009362: 
Neoplasm metastasis
$
Success rate
D000079822:Extranodal extension
0 Companies
0 Drugs
Success rate
D008207:Lymphatic metastasis
0 Companies
0 Drugs
Success rate
D009360:Circulating neoplastic cells
0 Companies
0 Drugs
Success rate
D009366:Neoplasm seeding
0 Companies
0 Drugs
Success rate
D009382:Unknown primary neoplasms
0 Companies
0 Drugs
Success rate
D061206:Neoplasm micrometastasis
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaIbandronic acid Ibandronic Acid Teva  2010-09-17   
Irinotecan Irinotecan  2008-02-27   
SandozIbandronic acid Ibandronic Acid Sandoz  2011-07-26   
Irinotecan Irinotecan  2008-02-27   
BayerLarotrectinib Vitrakvi 2029-10-21 2018-11-26   
RecordatiMechlorethamine Mustargen  1982-01-01   
Helsinn Birex PharmaceuticalsMechlorethamine Valchlor 2026-03-07 2013-08-23   
AmgenDenosumab Xgeva  2011-07-13 $2,191 M Q4/23-Q3/24 
SeagenTucatinib Tukysa  2021-02-11 $374.499 M Q4/22-Q3/23 
Atnahs PharmaceuticalsIbandronic acid Bondronat  1996-06-25   
Novast LaboratoriesIrinotecan Irinotecan  2017-05-26   
CiplaIrinotecan Irinotecan  2008-02-20   
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
77%
79/103
Phase 2
37%
49/133
Phase 3
19%
16/84
Approved: 7Overall Success rate: 5%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Bayer
Recordati
1
2
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use